The biopharmaceutical industry continues to navigate a complex development environment. Funding pressures, evolving supply chain strategies, geographic risk management, and increasing demands for speed and scalability are shaping how companies evaluate development and manufacturing partners.
These topics will be central to many conversations at the BIO International Conference 2026, taking place June 22–25 at the San Diego Convention Center. Olon will be exhibiting at Booth 4751, where attendees can meet with experts across small molecule development, high-potency APIs, antibody-drug conjugates (ADCs), and biotechnology manufacturing.
Representing Olon at BIO will be Andrea Conforto, VP Biotech CDMO Olon & Olon France, Amaia Mendivil, Biotech CDMO Business Development Manager, Kumar Rai Amit, Senior BD Sales and Marketing Olon France, and Laura Milbrandt, Senior Director of Business Development.
Addressing Today’s Development Challenges
Many emerging and established biopharmaceutical companies are facing increased pressure to advance programs while managing tighter budgets and more complex development decisions.
Funding remains a significant concern across the industry, particularly for early-stage companies. At the same time, organizations are placing greater emphasis on reducing risk throughout their supply chains. Many sponsors are actively evaluating manufacturing strategies that balance cost, geographic diversity, and long-term supply security.
As development programs progress toward clinical and commercial milestones, the selection of manufacturing partners has become increasingly important. Companies are looking for organizations that can provide flexibility, technical expertise, and scalable solutions that support long-term program success.
Supporting Development Through Commercialization
Olon provides development and manufacturing support across the product lifecycle, helping sponsors move programs from early development through commercial production.
At its U.S. manufacturing site near Cleveland, Ohio, Olon supports early-phase development activities through commercial GMP manufacture. As programs advance, additional scale-up opportunities are available throughout Olon’s global manufacturing network.
This approach allows sponsors to maintain continuity throughout development while minimizing the challenges often associated with transitioning projects between multiple providers. Leveraging established technical knowledge and internal technology transfer expertise can help reduce timelines, streamline development activities, and support more efficient progression into later clinical phases and commercial manufacturing.
A Global Network Designed for Flexibility
The ability to adapt manufacturing strategies has become increasingly valuable in today’s market.
Olon’s global network includes manufacturing capabilities across the United States, Europe, and India, allowing development programs to be structured around each sponsor’s specific goals and requirements.
For some companies, a fully U.S.-based manufacturing strategy may be the preferred path. Others may seek to leverage European capabilities or utilize a hybrid model that combines resources across multiple regions.
One approach gaining increased attention is the use of European manufacturing for upstream activities, followed by final manufacturing steps in the United States. This strategy can support reshoring initiatives, strengthen supply chain resilience, and provide additional flexibility for sponsors seeking to manage geographic risk.
Rather than applying a standard model to every project, Olon works collaboratively with clients to determine the most appropriate development and manufacturing pathway based on technical requirements, commercial objectives, and long-term supply considerations.
Expanding Awareness of U.S. Manufacturing Capabilities
To support the increasing focus on U.S.-manufactured APIs, Olon supports development and commercial manufacturing programs from its Cleveland-area facility, providing sponsors with a U.S.-based option for API development and production. As supply chain diversification and domestic manufacturing strategies continue to gain importance, these capabilities have become increasingly relevant for companies seeking additional manufacturing flexibility.
Organizations evaluating potential partners at BIO are encouraged to explore how Olon’s U.S. operations can support both early-phase and commercial manufacturing requirements.
High-Potency API and ADC Manufacturing Expertise
Interest in antibody-drug conjugates continues to grow as developers pursue increasingly targeted therapeutic approaches.
Olon has made significant investments in high-potency API manufacturing capabilities that support the development of ADC linker-payloads and other highly potent compounds. These capabilities position Olon to support companies working within one of the industry’s fastest-growing therapeutic areas.
As more ADC programs advance through development, access to experienced manufacturing partners with dedicated high-potency infrastructure will remain an important consideration for sponsors seeking to accelerate timelines and manage technical complexity.
Meeting the Full Spectrum of Biopharmaceutical Companies
BIO International attracts organizations from every stage of the drug development lifecycle, and Olon’s team is prepared to engage with a broad range of attendees.
Emerging biotech companies seeking development support, virtual organizations preparing for clinical studies, pharmaceutical companies evaluating supply chain strategies, and developers advancing complex small molecule, biologic, fermentation, or ADC programs can all benefit from discussions with Olon’s technical and business development experts.
The conference provides an opportunity to explore development challenges, evaluate manufacturing strategies, and identify practical solutions that align with both immediate project needs and long-term commercial goals.
Meet Olon at BIO International Conference 2026
BIO International Conference brings together decision-makers from across the global life sciences industry. It creates an environment where sponsors can discuss development challenges directly with experienced partners and evaluate strategies for advancing their programs.
The Olon team will be available throughout the conference at Booth 4751 to discuss API development, scale-up, high-potency manufacturing, ADC support, biotechnology manufacturing, supply chain strategies, and commercialization planning.
Companies preparing for clinical development, evaluating manufacturing partners, or seeking greater flexibility in their supply chains are encouraged to schedule a meeting with Olon during the BIO International Conference 2026. Start the conversation today to explore how Olon’s global network, technical expertise, and flexible development strategies can support the successful advancement of your next program.